Wyeth Marietta, Penn. Facility Shutdown To Mark End Of Influenza Program
Executive Summary
Wyeth will shut down the last element of its influenza vaccine program with the close of its Marietta, Penn. facility in December
You may also be interested in...
Fluarix Clears FDA; GSK Buys Vaccine Manufacturing Plant From Wyeth
GlaxoSmithKline is expanding its vaccine manufacturing capability as it prepares for its flu vaccine Fluarix to enter the U.S. market and in anticipation of several vaccine approvals over the next few years
Fluarix Clears FDA; GSK Buys Vaccine Manufacturing Plant From Wyeth
GlaxoSmithKline is expanding its vaccine manufacturing capability as it prepares for its flu vaccine Fluarix to enter the U.S. market and in anticipation of several vaccine approvals over the next few years
Paxil CR, Avandamet Seizure Threatens $1 Bil. In Annual Revenue For GSK
FDA's seizure of GlaxoSmithKline's Paxil CR and Avandamet threatens $1 bil. in annual revenues for the company
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: